STOCK TITAN

Zymeworks: EcoR1 Now Controls Nearly One-Third of Shares, per 13D

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

EcoR1 Capital, LLC and affiliates have filed a Schedule 13D disclosing a 30.7% beneficial stake in Zymeworks Inc. (NASDAQ: ZYME). The group, which includes EcoR1 Capital Fund Qualified, L.P. and EcoR1 founder Oleg Nodelman, now controls 22,970,388 common shares following the recent exercise of pre-funded warrants. The ownership percentage is based on 74,844,505 shares outstanding as reported in Zymeworks’ Form 8-K dated 27 Jun 2025.

Capital deployed. EcoR1 funds have invested a cumulative $205.7 million in ZYME equity: $192.9 million by the Qualified Fund and $12.9 million by EcoR1 Capital Fund, L.P. The totals include $50.0 million used on 26 Dec 2023 to acquire pre-funded warrants that have since been exercised.

Governance influence. Oleg Nodelman and EcoR1 employee Scott Platshon already sit on Zymeworks’ board, giving the investor direct insight and influence over corporate strategy. The filing states that the shares were acquired for investment purposes and that no specific plans under Items 4(a)-(j) of Schedule 13D are currently contemplated; however, EcoR1 reserves the right to buy or sell additional shares, engage in hedging, or discuss strategic matters with management and other shareholders.

Key takeaways for investors:

  • EcoR1 is now Zymeworks’ largest known holder, with voting and dispositive power shared among its entities.
  • The stake underscores EcoR1’s conviction that ZYME was undervalued at the time of purchase.
  • While the filing is not overtly activist, EcoR1’s 30%-plus position and board presence could accelerate strategic initiatives or heighten takeover speculation.
  • Potential share-price volatility may arise if EcoR1 materially increases or reduces its position.

Positive

  • EcoR1 now owns 30.7% of Zymeworks’ outstanding shares, indicating significant confidence in the company’s valuation and prospects.
  • More than $205 million of capital deployed to build the position, highlighting strong financial commitment.
  • Board representation by EcoR1 principals enhances alignment between the investor and corporate strategy.

Negative

  • High ownership concentration could reduce float and amplify volatility if EcoR1 changes its position.
  • Filing specifies right to sell or hedge at any time, creating an overhang risk for minority shareholders.

Insights

TL;DR: EcoR1’s 30.7% stake signals high conviction and creates a strategic overhang—generally bullish but watch concentration risk.

EcoR1 has deployed over $200 million to accumulate nearly one-third of ZYME’s equity, aligning its economic interests with other shareholders. Its board representation provides informational advantages and potential sway over capital-allocation decisions. Although the filing notes no current activist agenda, EcoR1 retains flexibility to push for transactions that could unlock value. From a portfolio standpoint, increased insider support typically lowers perceived downside risk and can attract additional institutional interest. That said, concentrated ownership heightens liquidity risk and could amplify price swings if EcoR1 trims its position. Overall impact skews positive given the scale of commitment and governance access.

TL;DR: Large insider-like stake improves oversight but raises minority-shareholder influence concerns; impact is material yet balanced.

EcoR1’s control of more than 30% of outstanding shares, coupled with two board seats, gives the fund substantial influence over strategic direction without triggering formal change-of-control mechanisms. The group expressly disclaims any current plans under Item 4, reducing immediate takeover risk. However, its ability to pivot quickly—buying more stock, advocating M&A, or exiting—creates an overhang that minority investors must monitor. Regulatory history shows no legal impediments, and funds were sourced from working capital, limiting financing uncertainty. Net-net, governance quality may improve through active oversight, but shareholder-rights implications warrant vigilance.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 74,844,505 shares of Common Stock outstanding following the exercise of Pre-Funded Warrants by the reporting persons, as reported in the Form 8-K filed by the Issuer on June 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 74,844,505 shares of Common Stock outstanding following the exercise of Pre-Funded Warrants by the reporting persons, as reported in the Form 8-K filed by the Issuer on June 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Percentage calculated based on 74,844,505 shares of Common Stock outstanding following the exercise of Pre-Funded Warrants by the reporting persons, as reported in the Form 8-K filed by the Issuer on June 27, 2025.


SCHEDULE 13D


EcoR1 Capital, LLC
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:06/27/2025
Oleg Nodelman
Signature:/s/ Oleg Nodelman
Name/Title:Reporting person
Date:06/27/2025
EcoR1 Capital Fund Qualified, L.P.
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:06/27/2025

FAQ

How many ZYME shares does EcoR1 Capital own after this filing?

EcoR1 and affiliates report 22,970,388 common shares, representing 30.7 % of shares outstanding.

What is the cost basis of EcoR1’s investment in Zymeworks?

The funds spent $205.7 million in aggregate, including roughly $50 million for pre-funded warrants acquired on 26 Dec 2023.

Does EcoR1 plan to take control of Zymeworks?

The Schedule 13D states no current plan or proposal for actions listed in Item 4(a)-(j), but EcoR1 may buy, sell, or engage with management as circumstances evolve.

Who represents EcoR1 on Zymeworks’ board of directors?

Oleg Nodelman, EcoR1’s manager, and Scott Platshon, an EcoR1 employee, currently sit on the board.

What percentage of Zymeworks’ shares was used to calculate EcoR1’s ownership?

Ownership is based on 74,844,505 shares outstanding, per Zymeworks’ Form 8-K filed 27 Jun 2025.
Zymeworks

NASDAQ:ZYME

View ZYME Stock Overview

ZYME Rankings

ZYME Latest News

ZYME Latest SEC Filings

ZYME Stock Data

1.83B
69.56M
Biotechnology
Pharmaceutical Preparations
Link
United States
MIDDLETOWN